

Chapter 2

PLACE OF BURSECTOMY IN GASTRIC CANCER SURGERY

Mehmet Akif ÜSTÜNER¹

INTRODUCTION

Gastric cancer is the 5th most prevalent cancer type worldwide and it has the 3rd rank in mortality rates.(Ferlay & et al,2015) Lymph node metastasis is considered to be one of the most significant prognostic factors in gastric cancer. D2 lymph node dissection is implemented as standard surgical treatment in the east Asia and in the West.(Wang &et al,2016) Bursa omentalis is defined as “Lesser peritoneal sac” in the Dictionary of Medical Terms .(Kocatürk,2005) It means “a smaller cavity/pouch of peritoneal cavity” in Turkish. In fact, even this definition itself forms the basis of various topics of discussion, that will be mentioned later on. The basis of this discussion is the reality that, no matter what you call it, bursa omentalis is a part of the peritoneum. Anatomically, liver, stomach and omentum lie in front of the omental bursa, and pancreas, left surrenal gland and kidney at the back. And it is connected to anterior peritoneal cavity by the foramen of Winslow.(Kayaalp,2015)

DEFINITION

Bursectomy is a procedure involving the resection of the anterior pancreatic capsule and anterior membrane of the transverse mesocolon along with omentectomy.

The objective is the en-bloc resection of post gastric cavity, eliminating free cancer cells and micrometastases, hence reducing recurrence rates. Yet another benefit is the removal of the lymph nodes located along the greater curvature of the stomach, enabling total excision of gastrocolic ligament forming the anterior-inferior of bursa.(Blouhos,Boulas & Hatzigeorgiadis,2013, Hundahl 2012) Bursectomy, defined as the removal of bursa omentalis, is a part of D2 dissection, and it requires experience to implement properly. However, oncologic benefits of bursectomy have become controversial in recent years, with the development of laparoscopic and robotic surgery.

¹ Op. Dr., Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Gastroenteroloji Cerrahisi
Ana bilim dalı, dr_ustuner@hotmail.com.

for Gastric Cancer”, it was stated that D2 lymph node dissection was the gold standard in stomach cancer, while withdrawal from bursectomy was observed worldwide. (Byrne & et al , 2018)

What was mentioned at the conclusion section of every article, namely prospective randomized controlled trial was finally revealed in 2018. In the study conducted in Japan by the participation of 57 hospitals, 1503 patients operated between 2010-2015 were included. The patients between 20-80 years of age, with BMI<30, T3,T4 adenocarcinoma pathology but no distal metastasis, who had distal or total gastrectomy (D2) but no chemoradiotherapy before were included. Along with exclusion criteria, 602+602, totally 1204 patients were enrolled. The term of experienced surgeon, which was stressed in every article, was defined; such that the surgeons who conducted more than 100 gastrectomy and more than 20 bursectomy were regarded as experienced surgeons to work with. An the end of the study it was concluded that bursectomy would not be considered as the standard treatment method for resectable cT3 or cT4 gastric cancer cases, because it could not prove any better survival rates than the alternatives. (Kurokawa & et al , 2018)

In conclusion, bursectomy requires operative experience like D2 lymph dissection (more than 100 gastrectomy and more than 20 bursectomy), with a rough and uneven learning curve. According to the results of the previous studies, the method was indicated to be useful only in T3-4 tumors with serosal invasion on the posterior wall (1965-2018:53). However, it was not recommended even in T3-T4 tumors since any oncologic benefit of bursectomy was not observed in the randomized controlled phase 3 trial reported in 2018. As a result, bursectomy is being abandoned in the world as well as in our country.

REFERENCES

1. Barreto, SG .& et al .(2015)Chaudhary A.Bursectomy for gastric cancer:what does the evidence indicate?Indian J Cancer,52(1):36-38, doi: 10.4103/0019-509X.175564.
2. Blouhos K, Boulas KA & Hatzigeorgiadis A.(2013) Bursectomy in gastric cancer surgery: surgical technique and operative safety. Updates Surg ,65:95-101. <https://doi.org/10.1007/s13304-013-0210-7>
3. Byrne BE, Rogers CA, & Blazeby JM.(2018).The end of bursectomy for gastric cancer? Lancet Gastroenterol Hepatol ,3(7):446-447. Published online April 27, 2018 [http://dx.doi.org/10.1016/S2468-1253\(18\)30135-3](http://dx.doi.org/10.1016/S2468-1253(18)30135-3)
4. Eom ,BW .& et al.(2013) Role of bursectomy for advanced gastric cancer: result of a casecontrol study from a large volume hospital. Eur J Surg Oncol ,39: 1407-1414, <https://doi.org/10.1016/j.ejso.2013.09.013>
5. Ferlay, Y.& et al (2015).Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer,1;136(5):359-386. <https://doi.org/10.1002/ijc.29210>

6. Fujita, J. & et al. (2012) Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. *Gastric Cancer* ,15:42-48. <https://doi.org/10.1007/s10120-011-0058>
7. Harbella, F.A. & et al. (2008) Gastrectomy and lymphadenectomy for gastric cancer: is the pancreas safe? *J. Gastrointest Surg* ,12;1912-1914. <https://doi.org/10.1007/s11605-008-0572-1>
8. Hundahl SA. (2012) The potential value of bursectomy in operations for transserosal gastric adenocarcinoma. *Gastric Cancer*,15:3-4. <https://doi.org/10.1007/s10120-011-0121-6>
9. Imamura, H. & et al. (2011). Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer: results of a randomized controlled trial. *World J Surg* , 35: 625-630. doi: 10.1007/s00268-010-0914-5.
10. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). (2011) *Gastric Cancer* ,14: 113-123. <https://doi.org/10.1007/s10120-011-0042-4>
11. Kayaalp C. (2015). Bursectomy at radical gastrectomy. *World J Gastrointest Surg* ; 7(10): 249-253. doi: 10.4240/wjgs.v7.i10.249
12. Kocatürk U. Açıklamalı Tıp Terimleri Sözlüğü. 2005, Nobel Tıp kitapevi.
13. Kochi, M. & et al. (2014) D2 gastrectomy with versus without bursectomy for gastric cancer. *Am J Clin Oncol*,37:222-226. doi: 10.1097/COC.0b013e31825eb734
14. Kurokawa, Y., & et al. (2018). Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol*,7;460-468 Published online April 27, 2018 [http://dx.doi.org/10.1016/S2468-1253\(18\)30090-6](http://dx.doi.org/10.1016/S2468-1253(18)30090-6)
15. Nakajima T. (2005) Historical Review of Research and Treatment of Gastric Cancer in Japan: Clinical Aspect. The Diversity of Gastric Carcinoma: Pathogenesis, Diagnosis, and Therapy. In: Kaminishi M, Takubo K, Mafune K, editors. Springer, 29-47. https://doi.org/10.1007/4-431-27713-7_2
16. Nie RC, & et al. (2018). Bursectomy for advanced gastric cancer: an update meta-analysis. *World Journal of Surgical Oncology*,16;66, doi: 10.1186/s12957-018-1354-1
17. Özer, İ. & et al. (2017) Changing Trends in Gastric Cancer Surgery. *Balkan Med J*,34:10-20. doi: 10.4274/balkanmedj.2015.1461
18. Shen, W.S. & et al. (2014). Effect of gastrectomy with bursectomy on prognosis of gastric cancer: a meta-analysis. *World J Gastroenterol* ,20:14986-14991. doi: 10.3748/wjg.v20.i40.14986
19. Wang, D. & et al. (2016) Treatment of Gastric Cancer With Paraaortic Lymph Node Metastasis. *Int Surg*,101:583-589. doi.org/10.9738/INTSURG-D-16-00148.1
20. Yamamura, Y. & et al. (2007) Distribution of free cancer cells in the abdominal cavity suggests limitations of bursectomy as an essential component of radical surgery for gastric carcinoma. *Gastric Cancer* ,10:24-28. <https://doi.org/10.1007/s10120-006-0404-5>
21. Yoon SS & Yang HK. (2009) Lymphadenectomy for gastric adenocarcinoma: should west meet the east? *Oncologist* ,14:871-882. doi: 10.1634/theoncologist.2009-0070
22. Zhang WH, & et al. (2015). Bursectomy and non-bursectomy D2 gastrectomy for advanced gastric cancer, initial experience from a single institution in China. *World J Surg Oncol* 2015 ,8;13:332, doi: 10.1186/s12957-015-0744-x